CRDL

Cardiol TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-21

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$1.80

+45.2% vs current

Most likely

Base case

45%

Probability

Target price

$0.95

-23.4% vs current

B-

Bear case

30%

Probability

Target price

$0.50

-59.7% vs current

AI sentiment snapshot

Latest data as of 2026-06-22

AI commentary

Primary company news flow is mildly constructive because April-May 2026 materials point to 75% MAVERIC enrollment, peer-reviewed Phase II publication support, and runway into Q4 2027 [#PR-2026-04-28] [#PR-EARNINGS-2026-05-07] [#PR-2026-04-01]. Still, this remains a low-conviction monitoring memo: analyst target count is unavailable, no reliable analyst revision or market-reaction packet is provided, social-context coverage is absent, and the deterministic score remains neutral with high uncertainty and weak evidence quality.

RankAlpha Sentiment Codex - 2026-06-22

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30eventMAVERIC enrollment completion is the key near-term inflectionHigh impact

Cardiol said on April 28, 2026 that MAVERIC enrollment had reached 75%, with target recruitment anticipated by the end of Q2 2026 and possibly extending into Q3 as additional U.S. sites come online; confirmation of full enrollment would modestly de-risk execution timing, but not the underlying Phase III efficacy risk [#PR-2026-04-28] [#PR-EARNINGS-2026-05-07].

2026-12-31catalystPeer-reviewed Phase II support helps the scientific setup ahead of pivotal dataHigh impact

The May 7, 2026 company release said Phase II MAvERIC results were accepted for publication in the Journal of the American Heart Association and highlighted reductions in pain, inflammation, and recurrent episodes with favorable tolerability; that strengthens external clinical credibility, although valuation still depends on Phase III translation [#PR-EARNINGS-2026-05-07].

2026-12-31catalystRunway into Q4 2027 and CRD-38 progress reduce immediate financing pressureHigh impact

The April 1, 2026 operations update said combined financings provided cash runway into Q4 2027 and that CRD-38 was being advanced toward an IND application and Phase I development; that supports operational continuity, but CardiolRx and MAVERIC remain the dominant valuation drivers [#PR-2026-04-01].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-22 • Updated nightlySource: Internal modelMethodology